Company profile: 4C Medical
1.1 - Company Overview
Company description
- Provider of minimally invasive therapies for structural heart disease, including AltaValve, a transcatheter mitral valve replacement device designed to treat mitral regurgitation by positioning above the native valve, preserving cardiac structures, and accommodating complex anatomies.
Products and services
- AltaValve: Transcatheter mitral valve replacement device treating mitral regurgitation by positioning above the native valve, preserving cardiac structures, and accommodating complex anatomies
- Minimally Invasive Therapy Development: Develops minimally invasive therapies for structural heart disease, including cardiac structure preservation and accommodation of complex anatomies
- Structural Heart Therapies Engineering: Engineers minimally invasive therapies targeting structural heart disease, aligning with mitral regurgitation treatment via above-native-valve positioning and cardiac structure preservation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4C Medical
Morphogen-IX
HQ: United Kingdom
Website
- Description: Provider of drug discovery developing bone morphogenetic proteins as a novel therapy for pulmonary arterial hypertension, a severe, life-limiting disease affecting lung blood vessels and leading to heart failure; founded in 2015 by Index Ventures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphogen-IX company profile →
Cardiol Therapeutics
HQ: Canada
Website
- Description: Provider of cannabidiol-based therapies for heart disease, including CardiolRx, an oral solution in clinical development to inhibit inflammatory pathways; CRD-38, a subcutaneous formulation for heart failure aiming to improve pharmacokinetics and therapeutic efficacy; and Phase II studies MAvERIC-Pilot (recurrent pericarditis) and ARCHER (acute myocarditis) evaluating safety, tolerability, efficacy, and impact on myocardial recovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardiol Therapeutics company profile →
enVVeno Medical
HQ: United States
Website
- Description: Provider of bioprosthetic devices for cardiovascular surgeries, including VenoValve, a surgically implanted one-way valve to restore proper blood flow in the femoral vein for patients with deep venous Chronic Venous Insufficiency (CVI), and enVVe, a non-surgical, transcatheter-based replacement venous valve for minimally invasive treatment of CVI in the deep veins of the leg.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full enVVeno Medical company profile →
Abionyx
HQ: France
Website
- Description: Provider of innovative therapeutic drugs for indications without effective or existing treatments, including rare diseases, with a focus on renal and ophthalmological conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abionyx company profile →
CardioGenics
HQ: Turkey
Website
- Description: Provider of sensitive diagnostic test products to the IVD market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CardioGenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4C Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4C Medical
2.2 - Growth funds investing in similar companies to 4C Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4C Medical
4.2 - Public trading comparable groups for 4C Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →